Biocomp - In Vitro Irritation Test (Medical device 10993-23)

Animal testing faces increasing ethical scrutiny and regulatory restrictions - validated alternative methods reducing animal use while maintaining predictive accuracy represent the future of safety assessment. In vitro skin irritation testing per ISO 10993-23 using MatTek EpiDerm™ reconstructed human epidermis provides human-relevant safety assessment while eliminating animal use through validated tissue construct methodology. The validated protocol exposes tissue constructs to test materials with subsequent MTT viability assessment providing quantitative data that predicts human skin responses, correlating with in vivo Draize scores through established prediction models. The reconstructed human epidermis model incorporates normal human keratinocytes forming stratified epithelium with functional barrier properties including stratum corneum, providing physiologically relevant tissue responses. Regulatory acceptance continues expanding with EU authorities preferring in vitro methods when validated alternatives exist, while global harmonization efforts promote alternative method adoption reducing animal testing. For medical device manufacturers, in vitro irritation testing provides earlier safety assessment during development screening materials before expensive in vivo studies, enables efficient material comparison testing multiple candidates rapidly, and demonstrates corporate responsibility regarding animal welfare. The quantitative viability data enables dose-response assessment revealing concentration-dependent effects, supporting formulation optimization minimizing irritation while maintaining functionality. Manufacturing validation confirms processing doesn't increase skin irritation potential, sterilization doesn't generate irritating degradation products, and aging maintains acceptable irritation profiles throughout shelf life. The human-derived tissue provides more relevant prediction of human responses than animal models, potentially reducing clinical surprises from species differences in skin sensitivity or metabolism.

No.
1006229
Method
MatTek EpiDerm™ reconstructed human epidermis model
Analyses category
Sample type
Finished device, Bulk material
Sample requirement (type)
Sterile or non sterile
Sample quantities
1 product
Equipment
multimode microplate reader
Lead Time Standard (Days)
10
Lead Time Express (Days)
unavailable
Lead Time Super Express (Days)
unavailable
Accredited
Yes
Test facility
In House
Add this test to cart to request an offer.

Do you need some help?

Other similar tests

ISO 10993-12, Ph.Eur. 2.2.44, USP 643, EN 1484
Chemistry - TOC (medical device) - analysis

Manufacturing residues invisible to visual inspection accumulate on medical device surfaces - machining coolants, mold releases, assembly lubricants - creating biocompatibility failures, cytotoxicity surprises, and regulatory obstacles that derail product launches after substantial development investment. Total Organic Carbon analysis for medical devices following the rigorous extraction protocols of ISO 10993-12 ensures that test conditions accurately simulate clinical use while meeting the analytical requirements of EN 1484, Ph. Eur. 2.2.44, and USP <643>. This comprehensive approach has become indispensable for three critical validation scenarios: cleaning validation during manufacturing line qualification where TOC verifies residue removal to safe levels, biocompatibility testing per ISO 10993-1 providing foundational chemical characterization before biological evaluation, and validation of cleaning processes for reusable medical devices according to AAMI ST98 demonstrating consistent organic residue removal. During manufacturing validation, TOC analysis verifies that cleaning processes consistently remove production residues - machining coolants, mold releases, adhesives, and assembly lubricants - to levels that won't compromise biocompatibility or device functionality. The extraction at physiologically relevant temperatures ensures complete recovery of both loosely bound surface contaminants and absorbed organic materials that could leach during clinical use, providing worst-case assessment. For biocompatibility assessment, TOC data provides the foundational chemical characterization required before biological testing, helping predict and interpret cytotoxicity results while supporting toxicological risk assessments per ISO 10993-17. When validating reprocessing procedures for reusable devices, TOC analysis proves that cleaning protocols achieve consistent organic residue removal across different soil challenges and device designs. The quantitative nature enables statistical process validation, demonstrating six-sigma cleaning effectiveness that visual inspection alone cannot provide.

ISO 10993-12, Ph.Eur. 2.2.44, USP 643, EN 1484
Chemistry - TOC (medical device) - method validation

Testing methods that fail to account for device-specific interference generate unreliable data that undermines cleaning validation, biocompatibility assessment, and regulatory submissions built on flawed measurements. Method validation for Total Organic Carbon analysis establishes that specific device materials won't interfere with accurate contamination measurement, a critical requirement before relying on TOC data for product release or cleaning validation decisions. Following ISO 10993-12 extraction protocols tailored to device clinical use and EN 1484 analytical requirements, this validation demonstrates recovery of organic contamination from unique material matrices through spiking studies with sucrose at multiple concentration levels. The validation process reveals whether device materials absorb organic compounds creating artificially low recovery, release interfering substances that elevate baseline readings, or require modified extraction conditions to achieve accurate results reflecting true contamination levels. For complex multi-material devices, validation ensures that extraction parameters - whether aggressive conditions for implantables or mild conditions for surface-contacting devices - effectively remove contaminants from all components without causing material degradation that artificially elevates TOC levels through polymer breakdown. Recovery studies typically target 70-130% spike recovery across three concentration levels spanning expected contamination range, establishing method linearity and detection limits specific to device materials and manufacturing processes. The validation data supports regulatory submissions by demonstrating that TOC testing produces reliable, reproducible results regardless of batch-to-batch material variations, supplier changes, or manufacturing process modifications. Failed validation reveals methodology limitations requiring optimization before expensive product testing, preventing wasted resources on unreliable data.